Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours

Abstract

The incidence and prevalence of neuroendocrine tumours (NETs) are on the rise, but to date, only complete surgical resection is curative. Among the various therapeutic options for metastatic disease, peptide receptor radionuclide therapy (PRRT), linking a radioactive moiety to an octreotide derivative, has been shown to be highly efficacious and a well‐tolerated therapy, improving progression‐free survival and prolonging overall survival. Nevertheless, complete responses are rare, and the current β‐particle emitters have non‐optimal radiobiological properties. A new generation of α‐particle‐emitting radionuclides is being developed, with the advantages of very high energy and a short path length. We survey the most recent developments in this field, summarising the result of currently performed studies in this potentially ground‐breaking novel form of therapy for NETs.